The UK Competition Authority alleges that two pharmaceutical companies have concluded a pay-for-delay agreement (Actavis / Concordia)

Competition Authority, UK

Previous article The EU Commission sends statements of objection for alleged pay-for-delay agreement (Teva / Cephalon) Next article The EU General Court confirms the EU Commission’s decision concerning its first pharma pay-for-delay case (Lundbeck)

3 Mar 2017

The UK Competition Authority alleges that two pharmaceutical companies have concluded a pay-for-delay agreement (Actavis / Concordia)

KEYWORDS

Reference

UK Competition Authority, Actavis / Concordia, Press Release, 3 March 2017

CMA alleges anti-competitive agreements for hydrocortisone tablets* The CMA today alleged that Concordia and Actavis signed illegal agreements which enabled high prices for a life-saving drug to be prolonged. The Competition and Markets Authority (CMA) alleges that between January 2013 and June 2016, Concordia (formerly Amdipharm), and Actavis UK (formerly Auden Mckenzie), entered into agreements under which Actavis UK incentivised Concordia not to enter the market with its own competing version of hydrocortisone tablets. In a statement of objections issued to

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

PDF Version

Author

UK Competition Authority
UK Competition & Markets Authority - CMA (London)

United Kingdom 351 contributions 88281 visits

Quotation

UK Competition Authority, The UK Competition Authority alleges that two pharmaceutical companies have concluded a pay-for-delay agreement (Actavis / Concordia), 3 March 2017, e-Competitions Pay-for-delay agreements, Art. N° 84194

Visites 208